These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28344804)

  • 1. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States.
    Banzhoff A
    Ther Adv Vaccines; 2017 Feb; 5(1):3-14. PubMed ID: 28344804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study.
    Mensah AA; Campbell H; Clark SA; Ribeiro S; Lucidarme J; Bai X; Borrow R; Ladhani SN
    Lancet Child Adolesc Health; 2023 Mar; 7(3):190-198. PubMed ID: 36736341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents.
    Biolchi A; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Budroni S; Giuliani MM; Rappuoli R; Boucher P; Pizza M
    Infect Dis Ther; 2021 Mar; 10(1):307-316. PubMed ID: 33185849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.
    Ladhani SN; Campbell H; Amin-Chowdhury Z; Lucidarme J; Borrow R; Ramsay ME
    Vaccine; 2022 Mar; 40(10):1493-1498. PubMed ID: 35148913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.
    Martinón-Torres F; Banzhoff A; Azzari C; De Wals P; Marlow R; Marshall H; Pizza M; Rappuoli R; Bekkat-Berkani R
    J Infect; 2021 Jul; 83(1):17-26. PubMed ID: 33933528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Awareness, attitudes, and practices on meningococcal serogroup B vaccination in the United States among parents of older adolescents and among young adults.
    Herrera-Restrepo O; Zhou Z; Krishnan A; Conley WJ; Oladele E; Multani JK; Tuly R; Shi L; Chen CC; Preiss S; Clements DE
    Curr Med Res Opin; 2024 Jan; 40(1):125-140. PubMed ID: 38032143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from mass vaccination response to meningococcal B outbreaks at US universities.
    Alderfer J; Isturiz RE; Srivastava A
    Postgrad Med; 2020 Sep; 132(7):614-623. PubMed ID: 32476532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.
    Soeters HM; Whaley M; Alexander-Scott N; Kanadanian KV; MacNeil JR; Martin SW; McNamara LA; Sicard K; Vanner C; Vuong J; Wang X; Bandy U; Patel M;
    Clin Infect Dis; 2017 Apr; 64(8):1115-1122. PubMed ID: 28158417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
    Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
    Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
    Nolan T; O'Ryan M; Wassil J; Abitbol V; Dull P
    Vaccine; 2015 Aug; 33(36):4437-45. PubMed ID: 26187261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
    Watson PS; Novy PL; Friedland LR
    Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.
    Srivastava A; Dempsey A; Galitsky A; Fahimi M; Huang L
    BMC Public Health; 2020 Jul; 20(1):1109. PubMed ID: 32664872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.